425: AVROBIO Addresses Stockholder Lawsuits and Provides Supplemental Disclosures Regarding Merger with Tectonic Therapeutic

AVROBIO, Inc. is supplementing disclosures related to its merger with Tectonic Therapeutic, Inc. to address stockholder lawsuits and demands alleging misrepresentations and omissions in the registration statement.

Summary

• AVROBIO, Inc. and Tectonic Therapeutic, Inc. entered into a merger agreement on January 30, 2024, where AVROBIO will acquire Tectonic.
• Following the merger announcement, three lawsuits were filed by AVROBIO stockholders, and eleven demand letters were received, alleging that the registration statement contained misrepresentations and omissions.
• To avoid potential delays and expenses, AVROBIO is voluntarily supplementing certain disclosures in the registration statement without admitting any liability or wrongdoing.
• The supplemental disclosures pertain to the background of the merger, including details of the initial proposal from Tectonic on November 11, 2023, which contemplated a valuation for AVROBIO of $70 million and Tectonic of $150 million, and a potential private placement of $125 million to $150 million.
• The disclosures also clarify that no AVROBIO employee entered into any agreement regarding continuing employment after the merger.
• The supplemental disclosures include updated charts related to the opinion of Houlihan Lokey to the AVROBIO Board, providing comparable company and transaction data.
• A special meeting of AVROBIO's stockholders is scheduled for June 11, 2024, to vote on the merger.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the stockholder lawsuits and the need for supplemental disclosures. While AVROBIO is taking proactive steps, the underlying issues raise concerns.

Positives

• AVROBIO is proactively addressing stockholder concerns by providing supplemental disclosures.
• The company is aiming to avoid potential delays and expenses associated with litigation.
• The supplemental disclosures provide additional information to stockholders, enhancing transparency.

Negatives

• The filing of stockholder lawsuits and demand letters indicates concerns about the merger and the disclosures made.
• AVROBIO is incurring expenses to address the lawsuits and provide supplemental disclosures.
• The need for supplemental disclosures suggests potential weaknesses in the initial registration statement.

Risks

• The outcome of the Merger Actions and Demands is uncertain.
• Additional complaints or demands may be filed or received.
• The merger could be delayed or blocked if the lawsuits are successful.
• The forward-looking statements are subject to risks and uncertainties, including the risk that the conditions to the Closing are not satisfied.

Future Outlook

The document contains forward-looking statements regarding the completion of the merger, the combined company's listing on Nasdaq, and the ownership structure of the combined company. These statements are subject to risks and uncertainties.

Management Comments

• AVROBIO believes that the Merger Actions and Demands are without merit.
• AVROBIO believes that the disclosures set forth in the Registration Statement comply fully with all applicable law, that no supplemental disclosures are required under applicable law, and that the allegations in the Merger Actions and Demands are without merit.
• AVROBIO specifically denies all allegations in the Merger Actions and the Demands and that any additional disclosure was or is required or material.

Industry Context

The document provides context by comparing AVROBIO and Tectonic to other companies in the cardiovascular and early-stage biotech sectors, as well as recent M&A transactions and IPOs in the industry. This helps investors understand the relative valuation and potential of the merger.

Comparison to Industry Standards

• The document includes detailed charts comparing AVROBIO to selected cardiovascular companies like Aerovate Therapeutics, Cereno Scientific, and Verve Therapeutics, based on metrics like share price, equity market value, and enterprise value.
• It also compares AVROBIO to early-stage companies like Acumen Pharmaceuticals, Apogee Therapeutics, and Structure Therapeutics, providing a broader context for valuation.
• The document analyzes recent M&A transactions, including deals involving DJS Antibodies (acquired by AbbVie) and Renovacor (acquired by Rocket Pharmaceuticals), to provide benchmarks for transaction values.
• It also includes data on recent biotech IPOs, such as Lexeo Therapeutics, Mineralys Therapeutics, and Structure Therapeutics, to assess market performance and investor sentiment.

Legal Proceedings

• Three actions have been filed by purported AVROBIO stockholders in connection with the merger: Garofalo v. Avrobio, Inc. et al., Price v. Avrobio, Inc., et al., and Keller v. Avrobio, Inc., et al.
• AVROBIO also received demand letters from eleven purported AVROBIO stockholders.

Stakeholder Impact

• The merger and related litigation could impact AVROBIO stockholders, employees, and other stakeholders.
• The supplemental disclosures aim to provide stockholders with more information to make informed decisions.
• The outcome of the merger will determine the future direction of the company and its impact on stakeholders.

Next Steps

• AVROBIO stockholders will vote on the merger at a special meeting on June 11, 2024.
• AVROBIO will continue to address the stockholder lawsuits and demands.
• The company will monitor and disclose any further developments related to the merger.

Key Dates